EVast Bio Achieves World's First Exosome Therapy Application for Knee Osteoarthritis
MIAMI, March 05, 2025 (GLOBE NEWSWIRE) -- EVast Bio, a U.S.-based clinical-stage biotech company, has achieved an important milestone by conducting the world's first human application of small extracellular vesicles (sEV) also called exosomes for osteoarthritis (OA) - EVA-100. According to a recent study published in the Journal of Nanobiotechnology, this achievement demonstrates promising results in inflammation control and cartilage protection offering a new therapeutic option for millions of patients suffering from OA. The research showcases a comprehensive development pipeline, from concept to first-in-human validation, marking a significant breakthrough in the treatment of knee osteoarthritis using clinical-grade sEV.
Osteoarthritis, a debilitating joint disease characterized by cartilage degradation and chronic inflammation, affects millions worldwide. Current treatments primarily focus on symptom management. This new study introduces a novel therapeutic approach using small extracellular vesicles (sEV) derived from umbilical cord mesenchymal stromal cells (UC-MSC) offering a potentially longer-lasting disease-modifying benefit.
'Our research marks a significant advancement in anti-inflammatory therapeutics with dual protective and regenerative potentials for osteoarthritis treatment,' the research team explains. 'We've developed a standardized, reproducible process for manufacturing clinical-grade extracellular vesicles, demonstrating remarkable potential in both preclinical and initial human studies,' comment Dr. Maroun Khoury, co-founder and Chief Scientific Officer of EVast Bio.
'EVA-100 could revolutionize osteoarthritis treatment, offering a transformative solution for millions if preclinical results are confirmed in both safety and efficacy clinical trials. Our approach aims to go beyond symptom relief by exploring the potential for cartilage regeneration, a key differentiator from existing therapies,' commented Matías Vial, Co-founder & CEO of EVast Bio.
Key Research Findings:
Innovative Manufacturing Process
The team established a standardized manufacturing protocol that meets Good Manufacturing Practice (GMP) standards, ensuring consistent production of clinical-grade sEV. This achievement marks a crucial step in bridging the gap between laboratory research and clinical application.
Highly Reproducible and Standardized sEV Manufacturing at EVast Bio
EVast Bio's proprietary platform has demonstrated a high level of reproducibility and standardization in the production of small extracellular vesicles (sEVs). Advanced molecular profiling of our sEVs has identified a consistent set of microRNAs (miRNAs) and proteins, reinforcing their stability and reliability for therapeutic applications. Notably, our research shows that a core group of highly specific miRNAs and proteins is consistently present across multiple donor-derived sEV samples.
Mechanism of Action
The study provides insights into how sEV combat osteoarthritis at the cellular level. Our researchers discovered that EVA-100 create an anti-inflammatory environment within affected joints by strategically guiding macrophages toward an anti-inflammatory state. This mechanism is supported by comprehensive miRNA and proteome analysis, highlighting the sophisticated molecular approach of the treatment.
A recently published study by the the Western Ontario Registry for Early OA (WOREO) Knee Study team suggests that while synovitis increases in OA, the exhaustion and dysfunction of immune-regulatory macrophages are linked to greater pain, making them a promising therapeutic target.
Preclinical Success
In preclinical studies using an OA mouse model, intra-articular injection of EVA-100 demonstrated positive therapeutic effects including hyaline cartilage regeneration – restoring joint function and mobility, a prolonged retention of sEV in the knee joint – ensuring sustained therapeutic action.
Pioneering a New Standard for OA Treatment
The therapy, EVA-100, leverages clinical-grade sEV derived from umbilical cord mesenchymal stromal cells (UC-MSC) and has shown transformational potential. Key highlights include:-World-First Human Application: EVA-100 was administered to a 56-year-old OA patient, achieving a significant WOMAC score reduction within six months and validated cartilage regeneration through third-party evaluation.-Regenerative Impact: Evidence of increased cartilage volume (WATSc) six months post-treatment underscores the therapy's capacity to restore joint health.-Strong Safety Profile: No adverse effects were reported during a 12-month follow-up, further validating the therapy's suitability for continued clinical development.
Beyond Osteoarthritis: A Next-Generation Drug Delivery Platform for small molecules.
EVast Bio's proprietary exosome-based platform extends far beyond osteoarthritis, offering a vehicle for advanced drug delivery across multiple therapeutic areas. By leveraging the natural tissue-targeting, immune-modulating, and cargo-loading capabilities of extracellular vesicles (EVs), EVast Bio is developing engineered exosomes designed for targeted delivery of small molecules, RNA therapeutics, and biologics. This customized approach has the potential to enhance bioavailability, reduce systemic toxicity, and enable new treatment strategies in oncology, neurodegenerative diseases, metabolic disorders, and autoimmune conditions.
With a robust GMP-compatible manufacturing process, strong IP portfolio, and growing clinical pipeline, EVast Bio is connecting with pharma and biotech partners to co-develop next-generation EV-based therapeutics that go beyond traditional drug delivery methods.
A Commercial Model Driving Innovation
EVast Bio is leading the exosome revolution in regenerative medicine with a clear strategy for commercialization and expansion:-Advanced Clinical Trials: EVA-100 is currently in Phase I trials (NCT06431152) with a dose-escalation protocol designed to refine safety and efficacy metrics.-Promising Results: Combined preclinical and clinical data showcase potential for cartilage repair and long-term joint health.-Pipeline Expansion: EVA-100+ is under development as an advanced drug-loaded exosome, including RNA loading targeting age-related conditions.-Strategic Partnerships: Actively pursuing collaborations to scale and license its proprietary sEV technology
Looking Ahead
The successful development and validation of this novel therapeutic approach opens new possibilities for OA treatment but also reinforces EVast Bio's position as a global leader in regenerative medicine and extracellular vesicle (EV) therapies. The research team has already initiated an early-phase clinical trials initiated this year; as detailed in the recently published, peer reviewed study.
'This comprehensive research pipeline, from development through preclinical testing to initial human validation, provides a strong foundation for advancing extracellular vesicle therapy in clinical practice,' the researchers note. 'The potential to offer a safe, effective, and locally-administered treatment for osteoarthritis patients represents a significant step forward in regenerative medicine,' highlights Dr. Maroun Khoury, who is also IMPACT Center director and CSO of Cells for Cells (C4C)—the center of excellence and biotech company sponsoring the study. C4C, the parent company from which EVast Bio was born, has played a crucial role in pioneering this innovation. EVast Bio, its US-based spinoff, presented the groundbreaking results of the first clinical case and trial design evaluating the safety and efficacy of EVA-100. These findings were showcased at prominent conferences, including ISCT and ISEV meetings held in San Francisco, Paris, Lyon, and Vancouver.
To fully leverage its exosome platform, C4C is launching a US-based spinoff focused on osteoarthritis (OA) and longevity. This new venture seeks to raise $18 million to fund the Phase IB studies of EVA-100 and accelerate the development of EVA-100+, an advanced drug-loaded exosome therapy targeting age-related conditions. The company is also pursuing co-development partnerships and expanding its portfolio with customized membrane-engineered and drug-loaded exosomes for additional therapeutic indications based on partners' interest. This strategic initiative strengthens EVast Bio as a leader in the $2.8 billion US exosomes market, aiming to deliver disease-modifying therapies to an estimated six million eligible patients. In osteoarthritis alone, the Serviceable Addressable Market (SAM) in the US is estimated at $7 billion, highlighting the vast commercial potential of exosome-based therapies in this space.
About the Research
Published in Journal of Nanobiotechnology (volume 23, Article number: 13, 2025), this study represents a collaborative effort to address one of the most common joint diseases affecting global health. The research combines expertise in regenerative medicine, cell biology, and clinical translation to develop an innovative therapeutic approach for osteoarthritis treatment.
For more information, please refer to the full study in the, Journal of Nanobiotechnology,
https://jnanobiotechnology.biomedcentral.com/articles/10.1186/s12951-024-03088-x
About EVast Bio: www.evast.bio
EVast Bio is a US-based clinical-stage biotech spinoff of Cells for Cells and Delaware C Corp pioneering the development of small Extracellular Vesicle (sEV) therapeutics. The proprietary platform harnesses these natural nano-vehicles – microscopic particles released by cells that facilitate intercellular communication – to create next-generation targeted delivery systems. The company innovative approach combines advanced sEV selection technology with precision engineering to develop therapeutics with enhanced safety and efficacy profiles. Through our patented technology, we produce sEVs with unique molecular signatures specifically tailored to target disease pathways. By optimizing drug delivery and reducing adverse events, EVast Bio is transforming the treatment landscape for challenging diseases. Our international clinical-stage pipeline demonstrates the potential of sEV technology to revolutionize therapeutic delivery and advance precision medicine.
About Cells for Cells:
C4C. (www.c4c.cl) is a clinical-stage company developing biotechnology platforms in South-America, including allogeneic cell therapies and extracellular vesicles. The company's mission is to enhance global healthspan by addressing key hallmarks of high-prevalence chronic diseases.
C4C previously raised $40 million USD, reinforcing its leadership in the biotechnology sector and accelerating the development of innovative therapies to improve patient outcomes worldwide. C4C is committed to time-sensitive and cost-efficient clinical and IP validation, a strategy that enable it to the first-ever clinical proof-of-principle of an exosome-produced therapy targeting joint disease.
Contact:CEO: mvial@c4c.clScientific related interest: maroun@evast.bioBusiness development interest: dsegura@c4c.cl
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, announced today that members of its senior management team will present and participate in the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11th at 10:00 am ET. A live webcast of the presentation can be accessed through the Investors section of the Company's website at Following the live presentation, a replay of the webcast will be available on the Company's website following the presentation date. About Lyell Immunopharma, Inc. Lyell is a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with hematologic malignancies and solid tumors. To realize the potential of cell therapy for cancer, Lyell utilizes a suite of technologies to endow CAR T cells with attributes needed to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical responses, including the ability to resist exhaustion, maintain qualities of durable stemness and function in the hostile tumor microenvironment. To learn more, please visit Contact: Ellen RoseSenior Vice President, Communications and Investor Relationserose@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
BonDo Seeks 100K USD Investments to Launch Innovative Brain Boosting Soup Brand by Year End
BonDo, a part of Për Brand Solutions, is seeking funding to accelerate its healthy soup product to market at a commercial scale. Atlanta, Georgia, June 11, 2025 (GLOBE NEWSWIRE) -- BonDo BonDo, a pioneering nutrition startup founded by brain science researcher Era Kovanxhi, is officially opening the door to investment opportunities as it seeks to raise $100,000 to bring its innovative 'stir-in' soup product to market. Backed by years of academic research and inspired by Kovanxhi's personal health journey, BonDo is on a mission to make nutrient-dense meals accessible and functional, offering investors both profit and purpose. 'BonDo was born from my personal struggles as a student, balancing academic rigor with skin health, energy crashes, and a demanding schedule,' says Kovanxhi, a scientist currently pursuing a PhD in Brain Science and Education. 'I started experimenting with vitamin combinations to help my body and brain perform better. When I saw the difference in myself and my family, I knew I had something meaningful to share.' Created as a solution for busy individuals in need of fast, nutrient-rich meals, BonDo's stir-in soup flavor bits combine ease of use with cutting-edge nutrition. Simply add water for a complete, flavorful soup that supports brain health, energy, skin health, calcium retention, and anti-aging benefits. BodDo VarietiesWith varieties such as BonDo Butter Bits, BonDo Leftovers, and BonDo Soup Booster Bits, each Bit has unique combinations of flavorful nodes of herbs, garlic, lemon, avocado, etc. For the ones with a sweet tooth and love for caffeine, it offers BonDo Coffee Milk Variety Bits, BonDo Coffee Flavor Booster Bits, and BonDo Oatmeal, with flavorful nodes from coffee, almond, hazelnut, and apple crisps, to name a few. The BonDo Baby variety contains healthy nutrients of wheat berry, butternut, chamomile, avocado, pumpkin, and vegetables. Part of Për Brand Solutions, this research-based initiative was developed to merge science-driven wellness with community-focused accessibility. Each BonDo mix includes core ingredients like chia seeds, rice, or dairy, naturally rich in Omega 3, Vitamin D & E, and calcium, nutrients that aid in everything from bone strength to cognitive clarity. These nutrient combinations are also being explored in Kovanxhi's current work on Klotho protein, a molecule linked to anti-aging, calcium retention, and blood sugar regulation. BonDo - How To UseAlready tested through small-batch, homemade orders, BonDo is now ready to scale production with the help of aligned investors. The funding will go toward manufacturing, packaging, continuous product refinement, expansion of flavor options, marketing, brand development, and the launch of sales operations ahead of the 2025 holiday season. Investors will receive a percentage of profits, making this both a high-potential business venture and a socially driven opportunity. 'BonDo is more than food. It's a response to the overwhelming demand for convenience without compromising wellness,' says Kovanxhi. 'This is created for people like myself and my community, those low on time and budget, but who still deserve high-quality, nourishing meals.' Media Contact Name: Era Kovanxhi Email: There is no offer to sell, no solicitation of an offer to buy, and no recommendation of any security or any other product or service in this article. Moreover, nothing contained in this should be construed as a recommendation to buy, sell, or hold any investment or security, or to engage in any investment strategy or transaction. It is your responsibility to determine whether any investment, investment strategy, security, or related transaction is appropriate for you based on your investment objectives, financial circumstances, and risk tolerance. Consult your business advisor, attorney, or tax advisor regarding your specific business, legal, or tax in to access your portfolio
Yahoo
4 hours ago
- Yahoo
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire Mazumdar, Ph.D., to the Company's Board of Directors, effective June 9, 2025. 'It is a privilege to welcome Claire to our Board, where she will draw from her strategic and operational experience in clinical-stage oncology to offer guidance as we prepare to initiate our Phase 3 ReDiscover-2 trial in breast cancer soon,' said Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics. Dr. Mazumdar is the founding Chief Executive Officer of Bicara Therapeutics (Nasdaq: BCAX), a clinical-stage oncology company. Prior to Bicara, Dr. Mazumdar led business development and corporate strategy at Rheos Medicines, where she supported the precision medicine company's global partnership with Roche Pharmaceuticals. Earlier in her career, she held a position at Third Rock Ventures, where she focused on company formation and business development. She holds a B.S. in biological engineering from the Massachusetts Institute of Technology and earned both an MBA from Stanford Graduate School of Business and a Ph.D. in cancer biology from Stanford School of Medicine. About Relay Therapeutics Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what's possible in drug discovery. Its Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics' initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit or follow us on Twitter. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding Relay Therapeutics' strategy, business plans and focus; the progress and timing of the clinical development of the programs across Relay Therapeutics' portfolio; the expected therapeutic benefits and potential efficacy and tolerability of RLY-2608, both as a monotherapy and in combination with other agents, and its other programs, as well as the clinical data for RLY-2608; the interactions with regulatory authorities and any related approvals; the potential market opportunity for RLY-2608; the cash runway projection; the expected benefits resulting from the implementation of the cost saving measures and potential ability to fund key value drivers; and the expectations regarding Relay Therapeutics' use of capital and expenses. The words 'may,' 'might,' 'will,' 'could,' 'would,' 'should,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'expect,' 'estimate,' 'seek,' 'predict,' 'future,' 'project,' 'potential,' 'continue,' 'target' and similar words or expressions, or the negative thereof, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: Relay Therapeutics' restructuring activities may be more costly or time-consuming than we expect or may not achieve their intended results; the timing, execution, and expected impact of Relay Therapeutics' restructuring plans (including the scope and timing of workforce reductions); the expected decrease in annual spending; the expected sufficiency of Relay Therapeutics' existing cash resources; the internal and external costs required for Relay Therapeutics' ongoing and planned activities, and the resulting impact on expense and use of cash, may be higher than expected, which may cause the company to use cash more quickly than expected or to change or curtail some of Relay Therapeutics' plans or both; the impact of global economic uncertainty, geopolitical instability and conflicts, or public health epidemics or outbreaks of an infectious disease on countries or regions in which Relay Therapeutics has operations or does business, as well as on the timing and anticipated results of its clinical trials, strategy, future operations and profitability; significant political, trade, or regulatory developments, such as tariffs, beyond Relay Therapeutics' control; the delay or pause of any current or planned clinical trials or the development of Relay Therapeutics' drug candidates; the risk that the preliminary or interim results of its preclinical or clinical trials may not be predictive of future or final results in connection with future clinical trials of its product candidates and that interim and early clinical data may change as more patient data become available and are subject to audit and verification procedures; Relay Therapeutics' ability to successfully demonstrate the safety and efficacy of its drug candidates; the timing and outcome of its planned interactions with regulatory authorities; and obtaining, maintaining and protecting its intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled 'Risk Factors' in Relay Therapeutics' most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Relay Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. Relay Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Contact:Pete Rahmerprahmer@ Media:Dan Budwick1AB973-271-6085dan@